Kentucky Department for Medicaid Services

Secretary for Health and Family Services Final PDL Selections from Pharmacy and Therapeutics Advisory Committee Meeting, January 19, 2006.

This chart provides a summary of the final PDL selections that were made by the Secretary for Health and Family Services as a result of the Pharmacy and Therapeutics Advisory Committee meeting of January 19, 2006.

	Description of Recommendation	Final PDL Decision
#1	**Oral Antivirals, Influenza Class Re-review** 1. The influenza antiviral agents are considered to be equivalent for safety and efficacy. **2.** DMS to prefer agents based on CDC recommendations. 3. DMS to consider CDC recommendation updates regarding antiviral therapy allowing the Medical Director to make an executive decision with Secretary approval until class can be considered at the next scheduled P & T meeting. 4. For any new chemical entity in the antiviral influenza agent class require a PA and quantity limit until reviewed by the P & T Advisory Committee.	Recommendations Approved PDL Selections **Neuraminidase inhibitors** RELENZA* TAMIFLU* * Based upon latest CDC recommendations
#2	**Alzheimer's Disease: Cholinesterase Inhibitors Class Review** 1. All agents in the Alzheimer's disease cholinesterase inhibitor class are equivalent in efficacy. 2. All agents in the Alzheimer's disease cholinesterase inhibitor class are equivalent in safety except for Cognex. 3. DMS to select agent(s) based on economic evaluation. 4. Namenda will be preferred without PA. 5. Agents not selected as preferred based on economic evaluation will require PA with implementation of electronic/POS step edit for failure of preferred agent. 6. DMS to allow patients to continue on current therapy. 7. For any new chemical entity in the treatment of Alzheimer's disease, require a PA and quantity limit until reviewed by the P&T Advisory Committee.	Recommendations Approved PDL Selections ARICEPT/ODT EXELON NAMENDA
#3	**Agents used in Multiple Sclerosis Class Review** 1. All agents in the multiple sclerosis class are considered clinically equivalent in efficacy and safety. 2. DMS to prefer all agents in class at this time. 3. For any new chemical entity in the Multiple Sclerosis class, require a PA and quantity limit until reviewed by the P&T Advisory Committee	Recommendations Approved PDL Selections AVONEX REBIF BETASERON COPAXONE